Literature DB >> 11583309

Increased level of von Willebrand factor is significantly and independently associated with diabetes in postinfarction patients. THROMBO Investigators.

W Zareba1, G Pancio, A J Moss, V G Kalaria, V J Marder, H J Weiss, L F Watelet, C E Sparks.   

Abstract

Diabetes is an established risk factor for reinfarction and cardiac death in postinfarction patients. Since the underlying mechanism of diabetes-related risk is not fully understood we aimed to evaluate the association between lipids, thrombogenic factors and diabetes in postinfarction patients. The study population consisted of 1,045 postinfarction patients (846 non-diabetic, 125 non-insulin- and 74 insulin-requiring diabetics) with the following blood tests performed 2 months after an index myocardial infarction: lipoprotein (a), apolipoprotein-B, apolipoprotein-A, cholesterol, HDL cholesterol, triglycerides, insulin, von Willebrand factor (vWF), fibrinogen, factor VII, D-dimer, and plasminogen activator inhibitor (PAI-1). After adjustment for relevant clinical covariates, non-insulin-requiring diabetes was significantly (p < 0.05) associated with elevated levels of (odd ratios per 1 log unit increase in parenthesis) vWF (1.74) and PAI-1 (1.42) whereas insulin requiring diabetes was associated with even more elevated levels of vWF (4.68), but not with increased levels of PAI-1. No significant differences in lipid levels were observed among three groups. In conclusion, increased level of von Willebrand factor is significantly and independently associated with diabetes in postinfarction patients, suggesting that endothelial damage is the primary mechanisms contributing to an increased occurrence of vascular and cardiac events in diabetic postinfarction patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11583309

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

1.  Clinical role of von Willebrand factor in acute ischemic stroke.

Authors:  Marija Menih; Miljenko Križmarić; Tanja Hojs Fabjan
Journal:  Wien Klin Wochenschr       Date:  2017-04-13       Impact factor: 1.704

Review 2.  The endocrine system in diabetes mellitus.

Authors:  Hisham Alrefai; Hisham Allababidi; Shiri Levy; Joseph Levy
Journal:  Endocrine       Date:  2002-07       Impact factor: 3.633

3.  Inflammatory markers modify the risk of recurrent coronary events associated with apolipoprotein A-I in postinfarction patients.

Authors:  Meng Wang; James Corsetti; Scott McNitt; David Q Rich; Charles E Sparks; Arthur J Moss; Wojciech Zareba
Journal:  J Clin Lipidol       Date:  2016-12-28       Impact factor: 4.766

4.  Sigesbeckia orientalis Extract Ameliorates the Experimental Diabetic Nephropathy by Downregulating the Inflammatory and Oxidative Stress Signaling Pathways.

Authors:  Chung-Ming Chen; Jer-Yiing Houng; Tsui-Ling Ko; Shu-Hui Juan; Hsiu-Chu Chou
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-05       Impact factor: 2.650

5.  Type II diabetes mellitus and cardiovascular risk factors: Current therapeutic approaches.

Authors:  Christos Kalofoutis; Christina Piperi; Anastasios Kalofoutis; Fred Harris; David Phoenix; Jaipaul Singh
Journal:  Exp Clin Cardiol       Date:  2007

6.  Vascular effects of ultrafine particles in persons with type 2 diabetes.

Authors:  Judith C Stewart; David C Chalupa; Robert B Devlin; Lauren M Frasier; Li-Shan Huang; Erika L Little; Steven M Lee; Richard P Phipps; Anthony P Pietropaoli; Mark B Taubman; Mark J Utell; Mark W Frampton
Journal:  Environ Health Perspect       Date:  2010-09-07       Impact factor: 9.031

7.  Influence of diabetes mellitus on heart failure risk and outcome.

Authors:  Christophe Bauters; Nicolas Lamblin; Eugène P Mc Fadden; Eric Van Belle; Alain Millaire; Pascal de Groote
Journal:  Cardiovasc Diabetol       Date:  2003-01-08       Impact factor: 9.951

Review 8.  Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies.

Authors:  James Yarmolinsky; Natália Bordin Barbieri; Tobias Weinmann; Patricia K Ziegelmann; Bruce B Duncan; Maria Inês Schmidt
Journal:  Sci Rep       Date:  2016-01-27       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.